Drug safety data mining with a tree-based scan statistic

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 5, 2013, Pages 517-523

  Kulldorff, Martin ^a,b   Dashevsky, Inna ^a   Avery, Taliser R ^a   Chan, Arnold K ^c,d   Davis, Robert L ^e   Graham, David ^f   Platt, Richard ^a,b   Andrade, Susan E ^b,g   Boudreau, Denise ^b,h   Gunter, Margaret J ^b,i   Herrinton, Lisa J ^b,e   Pawloski, Pamala A ^b,j   Raebel, Marsha A ^b,e   Roblin, Douglas ^b,e   Brown, Jeffrey S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HMO Research Network Center for Education and Research in Therapeutics   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d i3 Drug Safety   (United States)

^e KAISER PERMANENTE   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^h GROUP HEALTH RESEARCH INSTITUTE   (United States)

ⁱ LOVELACE CLINIC FOUNDATION   (United States)

^j HEALTHPARTNERS INSTITUTE   (United States)

more..

Author keywords

Adverse events; Clusters; Data mining; Drug safety surveillance; Pharmacoepidemiology; Pharmacovigilance; Scan statistics

Indexed keywords

GLIBENCLAMIDE; ITRACONAZOLE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TERBINAFINE;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; DATA BASE; DATA MINING; DIABETES MELLITUS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH CARE PLANNING; HEALTH MAINTENANCE ORGANIZATION; HUMAN; INFECTIOUS ARTHRITIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OSTEOMYELITIS; PRIORITY JOURNAL; SKIN DISEASE;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTIFUNGAL AGENTS; DATA MINING; DATABASES, FACTUAL; ELECTRONIC HEALTH RECORDS; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; HYPOGLYCEMIC AGENTS; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PHARMACOVIGILANCE; PRODUCT SURVEILLANCE, POSTMARKETING; YOUNG ADULT;

EID: 84877619276     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3423     Document Type: Article

References (43)

1. Committee on the Assessment of the US Drug Safety System. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington D.C.: Institute of Medicine of the National Academies; 2006.
2. Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The New Sentinel Network-improving the evidence of medical-product safety. N Engl J Med 2009; 361: 645-7.
3. Avorn J, Schneeweiss S. Managing drug-risk information-what to do with all those new numbers. N Engl J Med 2009; 361: 647-9.
4. Davis RL, Kolczak M, Lewis E, et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology 2005; 16: 336-41.
5. Platt R, Davis R, Finkelstein J, et al. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics. Pharmacoepidemiol Drug Saf 2001; 10: 373-7.
6. Yih WK, Kulldorff M, Fireman BH et al.. Active surveillance for adverse events: the experience of the vaccine safety datalink project. Pediatrics, 2011; 127: S54-64
7. Strom BL. Pharmacoepidemiology. 4th ed. West Sussex, England: Wiley; 2005.
8. Cesana M, Cerutti R, Grossi E, et al. Bayesian data mining techniques: the evidence provided by signals detected in single-company spontaneous reports databases. Drug Inf J 2007; 41: 11-21.
9. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999; 53: 177-90.
10. O'Neill R, Szarfman A. Some US Food and Drug Administration perspectives on data mining for pediatric safety assessment. Current Therapeutic Research 2001; 62: 650-63.
11. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002; 25: 381-92.
12. Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009; 18: 512-8.
13. Brown JS, Kulldorff M, Chan KA, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf 2007; 16: 1275-84.
14. Lieu TA, Kulldorff M, Davis RL, et al. Real-Time vaccine safety surveillance for the early detection of adverse events. Med Care 2007; 45: S89-S95.
15. Kulldorff M, Fang Z, Walsh SJ. A tree-based scan statistic for database disease surveillance. Biometrics 2003; 59: 323-31.
16. Raebel MA, Carroll NM, Simon SR, et al. Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. J Manag Care Pharm 2006; 12: 656-64.
17. Raebel MA, Lyons EE, Andrade SE, et al. Laboratory monitoring of drugs at initiation of therapy in ambulatory care. J Gen Intern Med 2005; 20: 1120-6.
18. Raebel MA, McClure DL, Simon SR, et al. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf 2007; 16: 55-64.
19. Simon SR, Andrade SE, Ellis JL, et al. Baseline laboratory monitoring of cardiovascular medications in elderly health maintenance organization enrollees. J Am Geriatr Soc 2005; 53: 2165-9.
20. Simon SR, Chan KA, Soumerai SB, et al. Potentially inappropriate medication use by elderly persons in U.S. Health Maintenance Organizations, 2000-2001. J Am Geriatr Soc 2005; 53: 227-32.
21. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006; 15: 369-86.
22. Chan KA, Davis RL, Gunter MJ, et al. The HMO Research Network. In: Strom B, ed. Pharmacoepidemiology. West Sussex, England: Wiley; 2005.
23. Clinical Classifications Software. 2010. (Accessed January, 2010, at http://www.ahcpr.gov/data/hcup/ccs.htm.)
24. Glaz J, Balakrishnan N, eds. Scan Statistics and Applications. New York: Birkhäuser Boston; 1999.
25. Glaz J, Naus D, Wallenstein S. Scan Statistics. New York: Springer; 2001.
26. Dwass M. Modified randomization tests for nonparametric hypotheses. Ann of Math Stat 1957; 28: 181-7.
27. Perveze Z, Johnson MW, Rubin RA, et al. Terbinafine-induced hepatic failure requiring liver transplantation. Liver Transpl. 2007; 13: 162-164.
28. Tokuyama Y, Senoh A, Setsu N, Iwatsuki K. Pustular psoriasis induced by terbinafine: differential diagnosis from acute generalized exanthematous pustulosis. Eur J Dermatol. 2008; 18: 725-726.
29. Marks DI, Pagliuca A, Kibbler CC, et al. IMPROVIT Study Group. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011; 155: 318-327.
30. Svejgaard E, Ølholm Larsen P, Deleuran M, Ternowitz T, Roed-Petersen J, Nilsson J. Treatment of head and neck dermatitis comparing itraconazole 200mg and 400mg daily for 1week with placebo. J Eur Acad Dermatol Venereol. 2004; 18: 445-449.
31. Vena GA, Micali G, Santoianni P, Cassano N, Peruzzi E. Oral terbinafine in the treatment of multi-site seborrhoic dermatitis: a multicenter, double-blind placebo-controlled study. Int J Immunopathol Pharmacol 2005; 18: 745-753.
32. Kohli R, Hadley S. Fungal arthritis and osteomyelitis. Infect Dis Clin North Am 2005; 19: 831-51.
33. Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol 2008; 126: 1740-1747.
34. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet 2009; 373: 2125-35.
35. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet 2007; 370: 1129-36.
36. Jones G, Macklin J, Alexander W. Contraindications to the use of metformin. Br Med J, 2003; 326: 4-5.
37. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol, 1998; 54: 315-321.
38. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and Dr S, 2001; 10: 483-486.
39. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf, 2004; 13: 519-523.
40. Schuemie MJ. Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. Pharmacoepidemiol Drug Saf, 2011; 20: 292-299
41. Huang L, Zalkikar J, Tiwari RC. A likelihood ratio test based method for signal detection with application to FDA's drug safety data. J Am Stat Assoc, 2011; 106: 1230-1241.
42. Brown J, Moore K, Braun M, et al. Active influenza vaccine safety surveillance: potential within a healthcare claims environment. Med Care 2009; 47: 1251-7.
43. Implementation of rapid cycle analysis for detection of potential excess risk of adverse events following influenza vaccination: a policy maker's guide 2009. (Accessed March, 2010, at http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/PostMarketActivities/UCM196254.pdf.)